APLS צמיחת הכנסות מרבעון לרבעון apellis.com

לוגו תאגידי של חברת Apellis (APLS)

Apellis Pharmaceuticals (APLS) attracts investment through its leadership in treating rare pathologies and the rapid success of Syfovre. This quarterly sales growth chart visualizes this momentum, where the value 61.00 reflects the metric's balance. Stable revenue is secured by lifelong therapy and patent protection. The company is currently focusing on the global distribution of its blockbuster through licensing, having temporarily stepped away from mergers.

APLS צמיחת הכנסות מרבעון לרבעון Apellis Pharmaceuticals, Inc. (04.07.2022 - 30.05.2026)

פילוחי מדדים ואנליטיקה של חברת Apellis Pharmaceuticals Inc (APLS)

- מחיר מניה ומחיר יעד קונצנזוס:
ניתוח כללי של החברה:APLS - Apellis Pharmaceuticals Inc
מוצר סדרתי של Apellis Pharmaceuticals, Inc.

The specifics of Apellis Pharmaceuticals (APLS) require significant expenditures to maintain strict temperature controls during the transport of ophthalmological drugs, which directly impacts operating margins. The dynamics of the quarterly revenue growth index allow for the separation of random market fluctuations from sustainable market share expansion by measuring sales growth rates compared to the same period last year to verify the fundamental strength of the business.

מתחרי מפתח